281 lines
9.1 KiB
Markdown
281 lines
9.1 KiB
Markdown
---
|
||
föreläsare: Martin Lidell
|
||
tags:
|
||
- biokemi
|
||
- aminosyrametabolism
|
||
- slides
|
||
date: 2025-12-08
|
||
---
|
||
# LPG001
|
||
Martin Lidell
|
||
Amino acid metabolism
|
||
|
||
## Lecture outline
|
||
Amino acids – a short introduction
|
||
How do we get access to amino acids?
|
||
Biosynthesis of non-essential amino acids
|
||
The origin of the a-amino group and the carbon skeleton
|
||
Degradation of amino acids
|
||
What happens with the amino group and the carbon skeleton?
|
||
The urea cycle
|
||
Transport of nitrogen to the liver (alanine/glutamine)
|
||
Examples of some defects in amino acid metabolism
|
||
|
||
## Amino acids
|
||
Definition:
|
||
An amino acid is a simple organic
|
||
compound containing both a carboxyl
|
||
and an amino group
|
||
More than 500 different amino acids
|
||
have been described in nature
|
||
Twenty a-amino acids (21 if including
|
||
selenocysteine) are commonly found
|
||
in mammalian proteins. These
|
||
proteinogenic amino acids are the
|
||
only amino acids that are coded for
|
||
by DNA
|
||
|
||
## Amino acids – examples of some important non-proteinogenic amino acids
|
||
GABA (g-amino acid)
|
||
g-aminobutyric acid (GABA)
|
||
an inhibitory neurotransmitter
|
||
Ornithine and Citrulline
|
||
intermediates in the urea cycle
|
||
Ornithine (a-amino acid)
|
||
Citrulline (a-amino acid)
|
||
|
||
## Why are amino acids essential biomolecules? – some examples
|
||
Building blocks in proteins
|
||
Precursors of important biomolecules
|
||
(neurotransmitters, hormones, etc. etc.)
|
||
Dopamine Epinephrine
|
||
Source of energy
|
||
Acts as neurotransmitters (e.g. Glu and Gly)
|
||
Involved in acid-base homeostasis (Gln)
|
||
Transport ammonia in a nontoxic form (Gln and Ala)
|
||
|
||
## Overview of amino acid metabolism
|
||
Endogenous proteins
|
||
De novo synthesis of non-essential amino acids
|
||
Dietary proteins
|
||
Synthesis of other important biomolecules
|
||
Degradation
|
||
Amino group → Urea
|
||
Carbon skeleton → Ketone bodies, Glucose/glycogen, Energy, CO2 + H2O, Fatty acids
|
||
Refilling reactions
|
||
Amino acids
|
||
Urea cycle
|
||
|
||
## Digestion of dietary proteins in the gastrointestinal tract
|
||
|
||
## Amino acids, di- and tripeptides are absorbed by the enterocytes and released as amino acids into the blood
|
||
The absorbed di- and tripeptides are digested by peptidases into free amino acids that are released into the blood
|
||
|
||
## Intracellular degradation of endogenous proteins – released amino acids can be reused
|
||
Proteasomal degradation
|
||
|
||
## Biosynthesis of amino acids – the a-amino group and the carbon skeletons
|
||
|
||
## Biosynthesis of amino acids – the a-amino group
|
||
The a-amino group is most often derived from glutamate
|
||
|
||
## Biosynthesis of amino acids – the carbon skeletons
|
||
|
||
## Most microorganisms can synthesize all of the common proteinogenic amino acids
|
||
|
||
## Biosynthesis of amino acids in humans – essential and nonessential amino acids
|
||
Nonessential:
|
||
Alanine, Arginine, Asparagine, Aspartate, Cysteine, Glutamate, Glutamine, Glycine, Proline, Serine, Tyrosine
|
||
Essential:
|
||
Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine
|
||
|
||
Humans cannot make the essential amino acids; they must be supplied in the diet
|
||
Some nonessential amino acids become essential under certain circumstances (“conditionally essential”)
|
||
e.g. arginine for fetus/neonate; tyrosine in PKU
|
||
|
||
## Biosynthesis of nonessential amino acids in humans
|
||
The carbon skeletons are derived from five precursors:
|
||
• 3-Phosphoglycerate
|
||
• Pyruvate
|
||
• a-Ketoglutarate
|
||
• Oxaloacetate
|
||
• Phenylalanine
|
||
|
||
## Formation of glutamate from a-ketoglutarate
|
||
Glutamate is primarily formed in transamination reactions catalyzed by different aminotransferases
|
||
|
||
## Aminotransferases / Transaminases
|
||
Enzymes transferring amino groups from a-amino acids to a-keto acids
|
||
a–amino acid-R1 + a–keto acid-R2 → a–keto acid-R1 + a–amino acid-R2
|
||
a-Ketoglutarate/Glutamate is the most common amino group acceptor/donor pair.
|
||
The reactions are reversible.
|
||
Essential for both synthesis and degradation of amino acids.
|
||
|
||
## ALT and AST – two important aminotransferases
|
||
Amino acids: Alanine, Aspartate, Glutamate
|
||
a-Keto acids: Pyruvate, Oxaloacetate, a-ketoglutarate
|
||
|
||
## Aminotransferases as indicators of tissue damage
|
||
• Intracellular enzymes
|
||
• Elevated plasma levels indicate cell damage
|
||
• ALT mostly in liver
|
||
• AST in liver, heart, skeletal muscle, kidney
|
||
|
||
## A second route of synthesis of glutamate from a-ketoglutarate
|
||
Glutamate dehydrogenase (mitochondrial, liver-specific)
|
||
|
||
## Arginine and proline – synthesized from glutamate
|
||
Arginine → part of urea cycle
|
||
|
||
## Glutamine and asparagine – formed by amidation
|
||
Enzymes: glutamine synthetase, asparagine synthetase
|
||
|
||
## Tyrosine – synthesized from phenylalanine
|
||
Reaction:
|
||
Phenylalanine + O2 + NADPH + H+ → Tyrosine + NADP+ + H2O
|
||
|
||
## Phenylketonuria (PKU)
|
||
Accumulation of phenylalanine, phenylpyruvate, phenyllactate, phenylacetate
|
||
Deficiency of tyrosine and metabolites
|
||
Autosomal recessive (PAH gene)
|
||
Hundreds of mutations
|
||
Insufficient phenylalanine hydroxylase activity
|
||
|
||
## PKU symptoms
|
||
Intellectual disability, delayed development, seizures, musty odor, fair skin/blue eyes
|
||
Treatment: dietary restriction, amino acid mix w/o Phe, tyrosine becomes essential, sapropterin may help
|
||
|
||
## “PKU-provet” – newborn screening since 1965
|
||
Blood sample after 48 hours
|
||
Purpose: detect treatable congenital diseases early
|
||
|
||
## Diseases included today (25 total)
|
||
Endocrine diseases (2)
|
||
Fatty acid metabolism defects (3)
|
||
Carnitine system defects (4)
|
||
Organic acidurias (6)
|
||
Urea cycle defects (3)
|
||
Amino acid metabolism defects (4)
|
||
Other metabolic diseases (2)
|
||
SCID
|
||
|
||
## Summary of part 1
|
||
(Amino acids important, sources, essential vs nonessential, aminotransferases, PKU)
|
||
|
||
## Excess amino acids cannot be stored
|
||
Amino acids not needed → degraded to intermediates that enter central metabolism
|
||
|
||
## How are amino acids degraded?
|
||
• Remove a-amino group
|
||
• Carbon skeleton becomes pyruvate, TCA intermediates, acetyl-CoA, acetoacetyl-CoA
|
||
Occurs primarily in liver; skeletal muscle degrades branched-chain amino acids
|
||
|
||
## Challenge: ammonia toxicity
|
||
Solution: liver → urea cycle
|
||
Other tissues → transport as glutamine/alanine
|
||
|
||
## Glutamate as intermediate toward urea
|
||
|
||
## a-amino groups transfer to a-ketoglutarate → glutamate (ALT/AST)
|
||
|
||
## Oxidative deamination of glutamate
|
||
Glutamate dehydrogenase (liver mitochondrial matrix)
|
||
|
||
## Serine and threonine can be directly deaminated (dehydratases)
|
||
|
||
## Side-chain nitrogen of glutamine and asparagine – release ammonia and form glutamate
|
||
|
||
## Ammonia is toxic to CNS
|
||
Urea cycle detoxifies ammonia
|
||
Only active in liver
|
||
|
||
## Urea cycle
|
||
Carbamoyl phosphate synthetase I
|
||
Ornithine transcarbamoylase
|
||
Argininosuccinate synthetase
|
||
Argininosuccinate lyase
|
||
Arginase
|
||
Urea contains 2 amino groups: one from NH4+, one from aspartate.
|
||
Carbon from HCO3–
|
||
|
||
## Why is ammonia toxic? (theory)
|
||
Glutamine synthetase in astrocytes → glutamine accumulation → osmotic swelling → edema
|
||
|
||
## Regulation of urea cycle
|
||
N-acetylglutamate activates CPS I
|
||
High glutamate + arginine → more N-acetylglutamate
|
||
|
||
## Defects in urea cycle – example: argininosuccinate lyase deficiency
|
||
Autosomal recessive
|
||
Symptoms: hyperammonemia, irregular breathing, hypotonia, vomiting, alkalosis, brain swelling, seizures
|
||
Treatment: glucose infusion, drugs promoting nitrogen excretion, dialysis, low-protein diet, liver transplant
|
||
|
||
## Drug treatment: arginine and phenylbutyrate
|
||
|
||
## Nitrogen transport from extrahepatic tissues
|
||
Extrahepatic tissues lack urea cycle
|
||
Transport forms: glutamine and alanine
|
||
Muscle uses BCAA
|
||
|
||
## Glutamine and alanine – nitrogen carriers
|
||
|
||
## Glucose-alanine cycle
|
||
|
||
## Where do carbon skeletons end up?
|
||
|
||
## Seven end-products of amino acid carbon skeleton degradation
|
||
|
||
## Citric acid cycle – source of building blocks
|
||
Cycle must be refilled (anaplerosis)
|
||
|
||
## Anaplerotic reactions
|
||
Pyruvate, amino acid skeletons refill TCA
|
||
|
||
## Glucogenic vs ketogenic amino acids
|
||
Glucogenic → pyruvate or TCA intermediates → glucose
|
||
Ketogenic → acetyl-CoA or acetoacetyl-CoA → ketone bodies
|
||
13 glucogenic
|
||
5 mixed (Phe, Iso, Thr, Trp, Tyr)
|
||
2 ketogenic only (Lys, Leu)
|
||
|
||
## Oxaloacetate as entry point for Asp/Asn
|
||
|
||
## a-Ketoglutarate as entry point for several amino acids
|
||
Glutamate → a-ketoglutarate (via GDH)
|
||
|
||
## Degradation pathways generating acetyl-CoA
|
||
|
||
## Degradation of phenylalanine and tyrosine
|
||
|
||
## Degradation of branched-chain amino acids
|
||
Occurs mainly in skeletal muscle
|
||
|
||
## Maple syrup urine disease (MSUD)
|
||
Autosomal recessive
|
||
Defect in branched-chain a-keto acid dehydrogenase complex
|
||
Accumulation of Leu, Iso, Val and their keto acids
|
||
Symptoms: poor feeding, vomiting, low energy, abnormal movements, delayed development; severe cases seizures/coma
|
||
Treatment: protein-restricted diet lacking Leu/Iso/Val; controlled supplementation
|
||
|
||
## Summary of part 2
|
||
• Amino acid degradation → ammonia → toxic
|
||
• Glutamate central
|
||
• Liver → only site of urea production
|
||
• Extrahepatic tissues use glutamine/alanine
|
||
• Carbon skeletons used for refilling, glucose, ketone bodies, fatty acids, energy
|
||
|
||
## Some important enzymes
|
||
ALT
|
||
AST
|
||
Glutamate dehydrogenase
|
||
Glutamine synthetase
|
||
Glutaminase
|
||
Phenylalanine hydroxylase
|
||
Carbamoyl phosphate synthetase I
|
||
|
||
## Läsanvisningar
|
||
Biochemistry (Berg et al.)
|
||
Chapter 23: 701–703, 708–731
|
||
Chapter 25: 766–790
|
||
Instuderingsfrågor på Canvas
|
||
Amino acid metabolism |